Standards for gene therapy clinical trials based on pro-active risk assessment in a London NHS Teaching Hospital Trust

QJM: An International Journal of Medicine

Volumn 98, Issue 2, 2005, Pages 75-86

  Bamford, K B ^a   Wood, S ^b   Shaw, R J ^c  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

^b Universal Safety Consultants Ltd   (United Kingdom)

^c HAMMERSMITH HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

GENE PRODUCT;

CLINICAL TRIAL; DNA MODIFICATION; DOCUMENTATION; EXPERIMENTAL DESIGN; GENE DELIVERY SYSTEM; GENE THERAPY; GENE VECTOR; HUMAN; INFECTION CONTROL; LAW; MEDICAL AUDIT; MICROBIAL GENETICS; NATIONAL HEALTH SERVICE; NONHUMAN; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROCESS DEVELOPMENT; REVIEW; RISK ASSESSMENT; SAFETY; STAFF TRAINING; STANDARD; TEACHING HOSPITAL; UNITED KINGDOM; WASTE MANAGEMENT;

EID: 14044278212     PISSN: 14602725     EISSN: None     Source Type: Journal    
DOI: 10.1093/qjmed/hci013     Document Type: Review

References (34)

1. Rubanyi GM. The future of human gene therapy. Mol Aspects Med 2001; 22:113-42.
2. St George JA. Gene therapy progress and prospects: adenoviral vectors. Gene Ther 2003; 10:1135-41.
3. Tsokos GC, Tsokos M. The TRAIL to arthritis. J Clin Invest 2003; 112:1315-17.
4. Dobbelstein M. Viruses in therapy-royal road or dead end? Virus Res 2003; 92:219-21.
5. Vile R, Ando D, Kirn D. The oncolytic virotherapy treatment platform for cancer: unique biological and biosafety points to consider. Cancer Gene Ther 2002; 9:1062-7.
6. Kaiser J. Gene therapy. RAC hears a plea for resuming trials, despite cancer risk. Science 2003; 299:991.
7. Kaiser J. Gene therapy. RAC's advice: proceed with caution. Science 2002; 298:2113-15.
8. Lai CM, Lai YK, Rakoczy PE. Adenovirus and adeno-associated virus vectors. DNA Cell Biol 2002; 21:895-913.
9. Evans ME, Lesnaw JA. Infection control for gene therapy: a busy physician's primer. Clin Infect Dis 2002; 35:597-605.
10. Graffunder EM, Venezia RA. Risk factors associated with nosocomial methicillin-resisant Staphylococcus aureus (MRSA) infection including previous use of antimicrobials. J Antimicrob Chemother 2002; 49:999-1005.
11. Bridges CB, Kuehnert MJ, Hall CB. Transmission of influenza: implications for control in health care settings. Clin Infect Dis 2003; 37:1094-101.
12. Knorr D. Human gene therapy: ensuring progress in the next millennium. Natl Forum 1999; 79:31-4.
13. Seymour LW. Trial and error. Lancet 2003; 361 1568.
14. Sullivan R. United Kingdom research governance strategy: reforming clinical research and development in England. Br Med J 2004; 328:49-50.
15. Dube ID, Cournoyer D. Gene therapy: here to stay. CMAJ 1995; 152:1605-13.
16. Griesenbach U, Geddes DM, Alton EW. Update on gene therapy for cystic fibrosis. Curr Opin Mol Ther 2003; 5:489-94.
17. Flotte TR. Gene therapy for cystic fibrosis. Curr Opin Mol Ther 1999; 1:510-16.
18. Gene Therapy Advisory Committee, 2004. [www.doh.gov.uk/genetics/gtac].
19. Scientific Advisory Committee on Genetically Modified Organisms (Contained Use), 2004. [http://www.hse.gov.uk/aboutus/meetings/sacgmcu/index.htm].
20. Medicines and Healthcare Products Regulatory Agency, 2004. [http://www.mhra.gov.uk].
21. Clinical Trials Directive (2001/20/EC), 2004.
22. The European Society of Gene Therapy, 2004. [www.abedi.se/esgt/index.html].
23. Genetically Modified Organisms (Contained Use) Regulations 2000. London, HMSO, 2000.
24. Health and Safety Executive, Advisory Committee on Genetic Modification Compendium of Guidance 2002. London, HMSO, 2002.
25. Health and Safety at Work Act 1974. London, HMSO, 1974.
26. Control of Substances Hazardous to Health (COSHH) Regulations 1999. London, HMSO, 1999.
27. Roberts G. Risk management methods. In: Risk Management in Healthcare, 2nd edn. London, Witherby, 2002:81-166.
28. Kubo H, Gardner TA, Wada Y, Koeneman KS, Gotoh A, Yang L, Kao C, Lim SD, Amin MB, Yang H, Black ME, Matsubara S, Nakagawa M, Gillenwater JY, Zhau HE, Chung LW. Phase I dose escalation clinical trial of adenovirus vector carrying osteocalcin promoter-driven herpes simplex virus thymidine kinase in localized and metastatic hormone-refractory prostate cancer. Hum Gene Ther 2003; 14:227-41.
29. Hedman M, Hartikainen J, Syvanne M, et al. Safety and feasibility of catheter-based local intracoronary vascular endothelial growth factor gene transfer in the prevention of postangioplasty and in-stent restenosis and in the treatment of chronic myocardial ischemia: phase II results of the Kuopio Angiogenesis Trial (KAT). Circulation 2003; 107:2677-83.
30. Burton EA, Fink DJ, Glorioso JC. Gene delivery using herpes simplex virus vectors. DNA Cell Biol 2002; 21:915-36.
31. Khan TA, Sellke FW, Laham RJ. Gene therapy progress and prospects: therapeutic angiogenesis for limb and myocardial ischemia. Gene Ther 2003; 10:285-91.
32. Bhagwanjee S, Muckart DJ, Jeena PM, Moodley P. Does HIV status influence the outcome of patients admitted to a surgical intensive care unit? A prospective double blind study. Br Med J 1997; 314 1077-81.
33. Agnihotri N, Bhasin DK, Vohra H, Ray P, Singh K, Ganguly NK. Characterization of lymphocytic subsets and cytokine production in gastric biopsy samples from Helicobacter pylori patients. Scand J Gastroenterol 1998; 33:704-9.
34. Papaluca Amati M, Pignatti F, Nolte A, Amerasinghe N, Gustafsson D, Moulon I, Le Courtois P. EMEA and Gene Therapy Medicinal Products Development in the European Union. J Biomed Biotechnol 2003; 2003:3-8.